Samsung BioLogics’ 'Super Plant' Reflects Robust Global COVID-19 R&D

Contract Manufacturing Demand Surging

 
• By Jung Won Shin

Samsung BioLogics’ construction of a fourth, large-scale manufacturing plant reflects increasing orders amid robust global COVID-19 R&D activities and further cements the Korean firm's position as the world's biggest contract biologics producer. 

Samsung BioLogics HQ
Investment, Capacity Of Samsung's Fourth Plant Bigger Than Expected • Source: Samsung BioLogics

More from South Korea

More from Focus On Asia